Adrienne G. Randolph

Adrienne G. Randolph

Auto-generated profile, based on publicly available information

Adrienne G. Randolph

Department of Anaesthesia and Pain Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Pediatric Critical Care Medicine
Verified
Journal Article
Closed access
BGBrahm Goldstein
Brahm Goldstein
BGBrett Giroir
Brett Giroir
ARAdrienne Randolph
Adrienne Randolph
Although general definitions of the sepsis continuum have been published for adults, no such work has been done for the pediatric population. Physiologic and laboratory variables used to define the systemic inflammatory response syndrome (SIRS) and organ dysfunction require modification for the developmental stages of children. An international panel of 20 experts in sepsis and clinical research from five countries (Canada, France, Netherlands, United Kingdom, and United States) was convened to modify the published adult consensus definitions of infection, sepsis, severe sepsis, septic shock, and organ dysfunction for children. Consensus conference. This document describes the issues surrounding consensus on four major questions addressed at the meeting: a) How should the pediatric age groups affected by sepsis be delineated? b) What are the specific definitions of pediatric SIRS, infection, sepsis, severe sepsis, and septic shock? c) What are the specific definitions of pediatric organ failure and the validity of pediatric organ failure scores? d) What are the appropriate study populations and study end points required to successfully conduct clinical trials in pediatric sepsis? Five subgroups first met separately and then together to evaluate the following areas: signs and symptoms of sepsis, cell markers, cytokines, microbiological data, and coagulation variables. All conference participants approved the final draft of the proceedings of the meeting. Conference attendees modified the current criteria used to define SIRS and sepsis in adults to incorporate pediatric physiologic variables appropriate for the following subcategories of children: newborn, neonate, infant, child, and adolescent. In addition, the SIRS definition was modified so that either criteria for fever or white blood count had to be met. We also defined various organ dysfunction categories, severe sepsis, and septic shock specifically for children. Although no firm conclusion was made regarding a single appropriate study end point, a novel nonmortality end point, organ failure-free days, was considered optimal for pediatric clinical trials given the relatively low incidence of mortality in pediatric sepsis compared with adult populations. We modified the adult SIRS criteria for children. In addition, we revised definitions of severe sepsis and septic shock for the pediatric population. Our goal is for these first-generation pediatric definitions and criteria to facilitate the performance of successful clinical studies in children with sepsis.

23 July 2020 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
LFLeora R. Feldstein
Leora R. Feldstein
ERErica B. Rose
Erica B. Rose
SHSteven M. Horwitz
Steven M. Horwitz
JCJennifer P. Collins
Jennifer P. Collins
MNMargaret M. Newhams
Margaret M. Newhams
ARAdrienne G. Randolph
Adrienne G. Randolph
Understanding the epidemiology and clinical course of multisystem inflammatory syndrome in children (MIS-C) and its temporal association with coronavirus disease 2019 (Covid-19) is important, given the clinical and public health implications of the syndrome. We conducted targeted surveillance for MIS-C from March 15 to May 20, 2020, in pediatric health centers across the United States. The case definition included six criteria: serious illness leading to hospitalization, an age of less than 21 years, fever that lasted for at least 24 hours, laboratory evidence of inflammation, multisystem organ involvement, and evidence of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on reverse-transcriptase polymerase chain reaction (RT-PCR), antibody testing, or exposure to persons with Covid-19 in the past month. Clinicians abstracted the data onto standardized forms. We report on 186 patients with MIS-C in 26 states. The median age was 8.3 years, 115 patients (62%) were male, 135 (73%) had previously been healthy, 131 (70%) were positive for SARS-CoV-2 by RT-PCR or antibody testing, and 164 (88%) were hospitalized after April 16, 2020. Organ-system involvement included the gastrointestinal system in 171 patients (92%), cardiovascular in 149 (80%), hematologic in 142 (76%), mucocutaneous in 137 (74%), and respiratory in 131 (70%). The median duration of hospitalization was 7 days (interquartile range, 4 to 10); 148 patients (80%) received intensive care, 37 (20%) received mechanical ventilation, 90 (48%) received vasoactive support, and 4 (2%) died. Coronary-artery aneurysms (z scores ≥2.5) were documented in 15 patients (8%), and Kawasaki’s disease–like features were documented in 74 (40%). Most patients (171 [92%]) had elevations in at least four biomarkers indicating inflammation. The use of immunomodulating therapies was common: intravenous immune globulin was used in 144 (77%), glucocorticoids in 91 (49%), and interleukin-6 or 1RA inhibitors in 38 (20%). Multisystem inflammatory syndrome in children associated with SARS-CoV-2 led to serious and life-threatening illness in previously healthy children and adolescents. (Funded by the Centers for Disease Control and Prevention.)

1 May 2011 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
NONaomi P. O'Grady
Naomi P. O'Grady
MAMary Alexander
Mary Alexander
LBLillian A. Burns
Lillian A. Burns
EDE. Patchen Dellinger
E. Patchen Dellinger
JGJeffrey Garland
Jeffrey Garland
SSSanjay Saint
Sanjay Saint
These guidelines have been developed for healthcare personnel who insert intravascular catheters and for persons responsible for surveillance and control of infections in hospital, outpatient, and home healthcare settings. This report was prepared by a working group comprising members from professional organizations representing the disciplines of critical care medicine, infectious diseases, healthcare infection control, surgery, anesthesiology, interventional radiology, pulmonary medicine, pediatric medicine, and nursing. The working group was led by the Society of Critical Care Medicine (SCCM), in collaboration with the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), Surgical Infection Society (SIS), American College of Chest Physicians (ACCP), American Thoracic Society (ATS), American Society of Critical Care Anesthesiologists (ASCCA), Association for Professionals in Infection Control and Epidemiology (APIC), Infusion Nurses Society (INS), Oncology Nursing Society (ONS), American Society for Parenteral and Enteral Nutrition (ASPEN), Society of Interventional Radiology (SIR), American Academy of Pediatrics (AAP), Pediatric Infectious Diseases Society (PIDS), and the Healthcare Infection Control Practices Advisory Committee (HICPAC) of the Centers for Disease Control and Prevention (CDC) and is intended to replace the Guideline for Prevention of Intravascular Catheter-Related Infections published in 2002. These guidelines are intended to provide evidence-based recommendations for preventing intravascular catheter-related infections. Major areas of emphasis include 1) educating and training healthcare personnel who insert and maintain catheters; 2) using maximal sterile barrier precautions during central venous catheter insertion; 3) using a > 0.5% chlorhexidine skin preparation with alcohol for antisepsis; 4) avoiding routine replacement of central venous catheters as a strategy to prevent infection; and 5) using antiseptic/antibiotic impregnated short-term central venous catheters and chlorhexidine impregnated sponge dressings if the rate of infection is not decreasing despite adherence to other strategies (i.e, education and training, maximal sterile barrier precautions, and >0.5% chlorhexidine preparations with alcohol for skin antisepsis). These guidelines also emphasize performance improvement by implementing bundled strategies, and documenting and reporting rates of compliance with all components of the bundle as benchmarks for quality assurance and performance improvement.

1 May 2011 in American Journal of Infection Control
Verified
Journal Article
Closed access
NONaomi P. O'GRady
Naomi P. O'GRady
MAMary Alexander
Mary Alexander
LBLillian A. Burns
Lillian A. Burns
EDE. Patchen Dellinger
E. Patchen Dellinger
JGJeffrey Garland
Jeffrey Garland
SSSanjay Saint
Sanjay Saint

16 March 2021 in JAMA
Verified
Journal Article
Open access
PDF file
LFLeora R. Feldstein
Leora R. Feldstein
MTMark W. Tenforde
Mark W. Tenforde
KFKevin G. Friedman
Kevin G. Friedman
MNMargaret Newhams
Margaret Newhams
ERErica Billig Rose
Erica Billig Rose
OIOvercoming COVID-19 Investigators
Overcoming COVID-19 Investigators
International reports of coronavirus disease 2019 (COVID-19)–related severe complications in children began in April 2020 when predominantly healthy children were hospitalized with cardiogenic shock or Kawasaki disease–like presentations temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.1-3 In mid-May 2020, the Centers for Disease Control and Prevention (CDC) published a case definition for multisystem inflammatory syndrome in children (MIS-C) for disease surveillance.4 Criteria were intentionally broad to facilitate data capture for diagnostic refinement. MIS-C was hypothesized to be mostly postinfectious and distinct from COVID-19 because many patients’ respiratory specimens were SARS-CoV-2 negative and MIS-C peaked after reported COVID-19 cases.5,6 Cardiovascular complications, such as ventricular dysfunction and coronary artery aneurysms, triggered recommendations for immunomodulatory treatments, including intravenous immunoglobulin (IVIG), corticosteroids, and biologics, and recommendations for intensive cardiac observation.5-9

1 December 1996 in Critical Care Medicine
Verified
Journal Article
Closed access
ARAdrienne G. Randolph
Adrienne G. Randolph
DCDeborah J. Cook
Deborah J. Cook
CGCalle A. Gonzales
Calle A. Gonzales
CPCharles G. Pribble
Charles G. Pribble
To evaluate the effect of real-time ultrasound guidance using a regular or Doppler ultrasound technique for placement of central venous catheters. We searched for published and unpublished research using MEDLINE, citation review of relevant primary and review articles, conference abstracts, personal files, and contact with expert informants. From a pool of 208 randomized, controlled trials of venous and arterial catheter management, eight published randomized, controlled trials were identified. In duplicate, independently, we abstracted data on the population, intervention, outcome, and methodologic quality. Ultrasound guidance significantly decreases internal jugular and subclavian catheter placement failure (relative risk 0.32; 95% confidence interval 0.18 to 0.55), decreases complications during catheter placement (relative risk 0.22; 95% confidence interval 0.10 to 0.45), and decreases the need for multiple catheter placement attempts (relative risk 0.60; 95% confidence interval 0.45 to 0.79) when compared with the standard landmark placement technique. When used for vessel location and catheter placement real-time, ultrasound guidance or Doppler ultrasound guidance improves success rates and decreases the complications associated with internal jugular and subclavian venous catheter placement. (Crit Care Med 1996; 24:2053-2058)